Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy.
Animals
Humans
Injections, Intraperitoneal
Mice
MicroRNAs
/ administration & dosage
Nanoparticles
/ administration & dosage
Pancreatic Neoplasms
/ drug therapy
Particle Size
Polymers
/ administration & dosage
RNA, Small Interfering
/ administration & dosage
Receptors, CXCR4
/ antagonists & inhibitors
Surface Properties
Tumor Cells, Cultured
CXCR4
immunosuppression
intraperitoneal administration
metastasis
miRNA-210
pancreatic cancer
tumor stroma
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
28 01 2020
28 01 2020
Historique:
pubmed:
14
1
2020
medline:
23
12
2020
entrez:
14
1
2020
Statut:
ppublish
Résumé
Nanomedicines achieve tumor-targeted delivery mainly through enhanced permeability and retention (EPR) effect following intravenous (IV) administration. Unfortunately, the EPR effect is severely compromised in pancreatic cancer due to hypovascularity and dense desmoplastic stroma. Intraperitoneal (IP) administration may be an effective EPR-independent local delivery approach to target peritoneal tumors. Besides improved delivery, effective combination delivery strategies are needed to improve pancreatic cancer therapy by targeting both cancer cells and cellular interactions within the tumor stroma. Here, we described simple cholesterol-modified polymeric CXCR4 antagonist (PCX) nanoparticles (to block cancer-stroma interactions) for codelivery of anti-miR-210 (to inactivate stroma-producing pancreatic stellate cells (PSCs)) and siKRAS
Identifiants
pubmed: 31927946
doi: 10.1021/acsnano.9b03978
pmc: PMC7041410
mid: NIHMS1554228
doi:
Substances chimiques
MicroRNAs
0
Polymers
0
RNA, Small Interfering
0
Receptors, CXCR4
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
255-271Subventions
Organisme : NCI NIH HHS
ID : R01 CA228524
Pays : United States
Organisme : NCATS NIH HHS
ID : R41 TR001312
Pays : United States
Références
Oncotarget. 2016 Mar 29;7(13):16396-408
pubmed: 26918939
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Mar;11(2):e1528
pubmed: 29700990
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Future Oncol. 2010 Oct;6(10):1625-41
pubmed: 21062160
ACS Nano. 2017 Feb 28;11(2):1466-1477
pubmed: 28099801
Oncotarget. 2014 Nov 30;5(22):11283-96
pubmed: 25526031
J Pharm Sci. 1985 Sep;74(9):915-21
pubmed: 4067845
J Control Release. 2013 Dec 28;172(3):782-94
pubmed: 24075927
Nat Nanotechnol. 2013 Oct;8(10):772-81
pubmed: 24056901
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Biomaterials. 2016 Sep;101:108-120
pubmed: 27267632
Nat Rev Drug Discov. 2016 Nov;15(11):771-785
pubmed: 27469033
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Theranostics. 2017 Apr 10;7(6):1689-1704
pubmed: 28529645
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Clin Invest. 2017 May 1;127(5):2007-2018
pubmed: 28414297
J Am Coll Surg. 2018 Apr;226(4):434-443
pubmed: 29331663
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Nat Commun. 2019 Apr 24;10(1):1894
pubmed: 31019193
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Transl Oncol. 2010 Apr;3(2):109-13
pubmed: 20360935
Pharmacol Ther. 2017 Nov;179:158-170
pubmed: 28549596
ACS Nano. 2017 Sep 26;11(9):8690-8706
pubmed: 28809532
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
J Clin Invest. 2012 Feb;122(2):639-53
pubmed: 22232209
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11453-11458
pubmed: 27663731
Gastroenterology. 2005 Oct;129(4):1237-50
pubmed: 16230077
Biomater Sci. 2015 Jul;3(7):1114-23
pubmed: 26146552
Adv Sci (Weinh). 2019 Sep 04;6(21):1900582
pubmed: 31728272
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Adv Drug Deliv Rev. 2017 Jan 1;108:13-24
pubmed: 27422808
J Am Coll Surg. 2014 Apr;218(4):573-85
pubmed: 24491244
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
Cancer Gene Ther. 2016 May;23(5):142-8
pubmed: 27080226
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4558-4566
pubmed: 30700545
Cell. 2016 Mar 10;164(6):1162-1171
pubmed: 26967283
J Control Release. 2014 Sep 28;190:451-64
pubmed: 24794900
Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8740-3
pubmed: 22855422
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):454-67
pubmed: 22710569
Nat Commun. 2018 Aug 23;9(1):3390
pubmed: 30139933
PLoS One. 2012;7(12):e49707
pubmed: 23226501
Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G709-17
pubmed: 18669622
Methods Mol Biol. 2018;1692:195-211
pubmed: 28986898
Nat Immunol. 2014 Apr;15(4):393-401
pubmed: 24608041
Vaccines (Basel). 2019 Jan 31;7(1):
pubmed: 30708956
Hepatology. 2015 May;61(5):1591-602
pubmed: 25529917
Cancer Metastasis Rev. 2012 Jun;31(1-2):397-414
pubmed: 22527451
Trends Mol Med. 2010 May;16(5):230-7
pubmed: 20434954
ACS Nano. 2018 Jul 24;12(7):6458-6468
pubmed: 29920064
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Cancer Gene Ther. 2016 Nov;23(11):373-381
pubmed: 27834358
Gene Ther. 2001 Apr;8(7):508-14
pubmed: 11319617
Pharm Res. 2010 May;27(5):735-8
pubmed: 20198409
Gut. 2015 Sep;64(9):1476-84
pubmed: 25994217
Mol Cancer Ther. 2018 Nov;17(11):2377-2388
pubmed: 30097486
Biomaterials. 2016 Sep;101:285-95
pubmed: 27310916
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
J Clin Invest. 2008 Apr;118(4):1398-404
pubmed: 18317595
Cancer Res. 2013 Jun 1;73(11):3235-47
pubmed: 23633488
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72
pubmed: 20101258
Cell. 2012 Apr 27;149(3):656-70
pubmed: 22541435
Am J Physiol Renal Physiol. 2005 Mar;288(3):F433-42
pubmed: 15692055
Cancer Sci. 2011 Jan;102(1):200-5
pubmed: 20942868
Theranostics. 2018 Jul 30;8(16):4305-4320
pubmed: 30214622
FEBS Lett. 2017 Jul;591(14):2167-2179
pubmed: 28643334
J Clin Oncol. 2015 Dec 20;33(36):4284-92
pubmed: 26527777